# EDGAR Filing Document

**Accession Number:** 0001781905
**File Stem:** 0001729149-23-000016
**Filing Date:** 2023-1
**Character Count:** 11745
**Document Hash:** 83f71ae401f948fbefaad647f5d7ec13
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001729149-23-000016.hdr.sgml**: 20230118

**ACCESSION NUMBER**: 0001729149-23-000016

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230117

**FILED AS OF DATE**: 20230118

**DATE AS OF CHANGE**: 20230118

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Moore Michael
- **CENTRAL INDEX KEY:** 0001781905

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38973
- **FILM NUMBER:** 23535552

**MAIL ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** VIEMED HEALTHCARE, INC.
- **CENTRAL INDEX KEY:** 0001729149
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** A1
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508
- **BUSINESS PHONE:** 337.504.3802

**MAIL ADDRESS:**
- **STREET 1:** 625 E. KALISTE SALOOM RD.
- **CITY:** LAFAYETTE
- **STATE:** LA
- **ZIP:** 70508

## Ex-24

```
<pre>
Ex. 24

LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

Know all by these presents, that the undersigned hereby constitutes and appoints Jesse Bergeron, Todd Zehnder, and Trae Fitzgerald, or any of them acting singly and with full power of substitution, the undersigned's true and lawful attorney-in-fact to:

(l)    prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section l6(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC;

(2)    execute for and on behalf of the undersigned, in the undersigned's capacity as an officer and/or director of Viemed Healthcare, Inc. (the "Company"), Forms 3, 4, and 5 in accordance with Section l6(a) of the Securities Exchange Act of 1934 and the rules thereunder;

(3)    do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4, or 5 and timely file such form with the Securities and Exchange Commission and any stock exchange or similar authority;

(4)    seek or obtain, as the undersigned's representative and on the undersigned's behalf, information on transactions in the Company's securities from any third party, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to each of the undersigned's attorneys-in-fact appointed by this Limited Power of Attorney and approves and ratifies any such release of information; and

(5)    take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this  Limited Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.

This Limited Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

In affixing his or her signature to this Limited Power of Attorney, the undersigned hereby revokes any and all previously executed Powers of Attorney for the same or similar purposes.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of September, 2022.

/s/ Michael Moore
Michael Moore
</pre>
```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Moore Michael<br><sub>(Last) (First) (Middle)</sub><br>625 E. KALISTE SALOOM RD.<br><sub>(Street)</sub><br>LAFAYETTE, LA 70508<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2023-01-17 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>VIEMED HEALTHCARE, INC. [ VMD ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Shares | 2023-01-18 |  | M |  | 9490 | A | <sup>(1)</sup> | 1815299 | D |  |
| Common Shares | 2023-01-18 |  | D |  | 9490 | D | $7.77 | 1805809 | D |  |
| Common Shares | 2023-01-18 |  | M |  | 18979 | A | <sup>(2)</sup> | 1824788 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Phantom Share Units | <sup>(1)</sup> | 2023-01-18 |  | M |  |  | 9490 | <sup>(3)</sup> | 2025-01-18 | Common Shares | 9490.0 | $0 | 18978 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | 2023-01-18 |  | M |  |  | 18979 | <sup>(4)</sup> | 2025-01-18 | Common Shares | 18979.0 | $0 | 37958 | D |  |
| Phantom Share Units | <sup>(5)</sup> | 2023-01-17 |  | A |  | 20205 |  | <sup>(6)</sup> | 2026-01-17 | Common Shares | 20205.0 | $0 | 20205 | D |  |
| Restricted Stock Units | <sup>(2)</sup> | 2023-01-17 |  | A |  | 80818 |  | <sup>(7)</sup> | 2026-01-17 | Common Shares | 80818.0 | $0 | 80818 | D |  |

---

### Footnotes:

(1) Represents vesting of cash-settled phantom shares granted under the Issuer's Phantom Share Unit Plan. Each phantom share is the economic equivalent of one share of the Company's common shares. The settlement of the phantom shares for cash is reported on this Form 4 as a disposition of the phantom shares being settled in exchange for the acquisition of the underlying Company common shares, and a simultaneous disposition of the underlying Company common shares to the Company for cash.

(2) Each Restricted Stock Unit (RSU) represents a contingent right to receive one common share.

(3) Represents an award granted on January 18, 2022 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

(4) Restricted Stock Units (RSUs) granted to reporting person on January 18, 2022, which vest in three equal annual installments beginning on the first anniversary of the grant date.

(5) Each phantom share represents a right to receive the cash value of one share of the Issuer's common shares which will be determined based on the Issuer's share price on the vesting date.

(6) Represents an award granted on January 17, 2023 under the Issuer's Phantom Share Unit Plan which vests in three equal annual installments beginning on the first anniversary of the grant date.

(7) Restricted Stock Units (RSUs) granted to reporting person on January 17, 2023, which vest in three equal annual installments beginning on the first anniversary of the grant date.

**Remarks:**
Exhibit List:
    -Exhibit 24  Limited Power of Attorney

**Signature:** /s/ Jesse Bergeron, Attorney-in-Fact  
**Date:** 2023-01-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**